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Available online 2 September 2015Background: In elderly patients with HER2-positive breast cancer, few data on efficacy and
toxicity of adjuvant trastuzumab treatment exists since older patients were in general
excluded from large randomized studies. This prospective observational study aimed to
confirm the beneficial findings from pivotal trials in age cohorts ≥65 years.
Materials and Methods: There were no restrictions for recruitment with respect to age or
concomitant/sequential adjuvant medication. Long-term relapse/survival status of the
patients was assessed once a year.
Results: Among the 3940 evaluable patients enrolled between 2006 and 2012 at 339
institutions, 507 were aged between 65 and 69 years, with another 507 patients ≥70 years.
Elderly patients suffered from significantly more advanced primary tumors. Preceding or
concomitant chemotherapy showed decreasing aggressivenesswith patient's age. Trastuzumab
treatment was stopped prematurely in only 11% of the elderly, but more often than in younger
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463J O U R N A L O F G E R I A T R I C O N C O L O G Y 6 ( 2 0 1 5 ) 4 6 2 – 4 6 9inferior relapse-free survival when adjusted for other relevant prognostic factors (hazard ratio:
1.01 per year; p = 0.24). Three-year overall survivalwas significantly lower in thepopulation older
than 64 years than in younger patients (94.2% vs. 96.8%, p = 0.0011).
Conclusions: To our knowledge, our population of elderly patients treated with adjuvant
trastuzumab is the largest analyzed so far. The beneficial long-term results were comparable
to those in the younger cohorts. Although the risk of cardiotoxicity increased significantlywith
age, it also remained manageable in older patients. Thus, chronological age alone should not
preclude HER2 antibody treatment.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
More than 30% of patients diagnosed with breast cancer world-
wide are beyond the age of 65 years, and this proportion is even
distinctly higher (up to more than 50%) in developed countries
with a longer overall life expectancy.1–3 This corresponds to
incidence rates of about 400 per 100,000 in Western European
countries and the USA. Nevertheless, the evidence base for
aggressive antineoplastic treatment of elderly patients is limited,
although it is generally accepted that specific aspects have to be
taken into account in this subpopulation, such as comorbidity,
concomitant medication, susceptibility to toxic effects, and
compliance.4,5 The lack of data in elderly patients with breast
cancer results from the trend to exclude older and/or comorbid
patients from randomized phase III trials, especially those
focusing on newly developed treatments.4–8 Therefore, rec-
ommendations, such as those compiled by the International
Society of Geriatric Oncology (SIOG) mostly have to rely on
the extrapolation of data from younger patients, with respect to
efficacy, and to toxicity-driven contraindications, precautions, or
usage restrictions.4
In elderly patients, the introduction and consecutive im-
provement of adjuvant chemotherapy seems to have a smaller
impact on outcome, especially on mortality.5,9 This finding
may, however, be explained by the fact that this patient group
received less systemic treatment.2,5,10 This attitude corresponds
to the assumption that in older patients breast cancermay be in
general less aggressive, and usually hormone receptor–positive
and human epidermal growth factor receptor 2 (HER2)–negative.2
Moreover, it certainly reflects toxicity concerns. On the other
hand, as recently shown in SEER (Surveillance, Epidemiology,
and End Results) database research, adjuvant treatment-related
mortality was very low in the elderly population.11 It is now
generally accepted that age, by itself, should not be a barrier to
aggressive tumor therapy, and that the treatment objectives (e.g.
improving quality of life, preserving functional autonomy, or
avoiding hospitalization rather than achieving relapse-free
survival) may differ between elderly and younger patient
populations.2,4
In the last decade, treatment of HER2-positive, localized
breast cancer was revolutionized by the early results from large
pivotal studies of adjuvant chemotherapy combined with the
HER2-directed monoclonal antibody trastuzumab12–17 convinc-
ingly underpinned by several meta-analyses.18–20 However,
because the number of elderly patients in these large trials was
rather small, treatment guidelines are less well established in
this population.6,21 In fact, the incidence of HER2-positivity in
elderly patients is still not well described,3,6,10 although theNational Comprehensive Cancer Network (NCCN) recently
reported 26%of patientswith HER2-positive, early breast cancer
to be 60 years or older.22 Current estimates indicate that the
proportion of HER2-positive cases among elderly patients with
breast cancer is 10% to 20%,which is notmuch different from the
incidences reported for the entire breast cancer population.10
After approval of trastuzumab (Herceptin®) for the treat-
ment of early breast cancer in Germany in 2006 (without
any restrictions with respect to age), we embarked on this
non-interventional observation study to obtain data on the
clinical management of the overall population of HER2-positive
patients with early breast cancer. The only selection criterion
was the decision to receive adjuvant trastuzumab treatment,
and we made no restrictions on age, comorbidity, or treatment
regimen, which permitted the inclusion of patients receiving
endocrine combinations or trastuzumab monotherapy.
The definition of "elderly" is somewhat controversial. The
cutoff at 65 years is in linewith a statement by the International
Conference on Harmonization,23 also reflecting that physicians
usually treat patients differently from this age onwards.5
However, 70 years might be a clinically more useful threshold,
as relevant age-related changes seem to sharply increase only
between 70 and 75 years.5 Therefore, we analyzed the data
for the patient groups aged 65 to 69 years and aged ≥70 years
separately, which was justified because the number of patients
in our cohort was large.2. Methods
2.1. Patient Population and Methods of Observation
This non-interventional observation study focused on patients
with early breast cancer who received trastuzumab after its
approval in Germany. Investigators were asked to report on a
pre-specified number of consecutive patients fulfilling this
criterion. All types of previous or concomitant adjuvant
treatments (endocrine or chemotherapy) were acceptable.
For inclusion, HER2 positivity had to be confirmed, usually
defined as 3+ staining in immunochemistry or a positive
result of fluorescence in situ hybridization (FISH) in case of 2+
staining. Patients were treated in accordance with routine
practices of the respective institution, and findings were
prospectively documented on standardized case report forms
(CRF). There were no further restrictions with respect to
individual diagnostic and therapeutic procedures before and
after patient registration. Course of disease and treatment were
closelymonitored, either until (premature) trastuzumab therapy









Median (range) [kg] 69 (40–178) 70 (46–168) 70 (44–121)
ECOG performance status
0 1878 (65%) 283 (56%) 250 (50%)
1 977 (34%) 204 (41%) 231 (46%)
2 34 (1%) 14 (3%) 18 (4%)
3 – – 3 (1%)
4 1 (0%) – –
Primary tumor stage
pTis 243 (9%) 33 (7%) 30 (6%)
pT1 1190 (42%) 187 (38%) 182 (36%)
pT2 1105 (39%) 227 (46%) 227 (45%)
pT3 154 (5%) 21 (4%) 30 (6%)
pT4 80 (3%) 20 (4%) 24 (5%)
TX 81 (3%) 9 (2%) 11 (2%)
Lymph node stage
pN0 1550 (53%) 282 (56%) 233 (46%)
pN1 799 (27%) 120 (24%) 137 (27%)
pN2 313 (11%) 53 (10%) 73 (14%)
pN3 182 (6%) 42 (8%) 48 (9%)





Stage I 964 (35%) 149 (31%) 130 (26%)
Stage II 1277 (46%) 232 (48%) 234 (48%)
Stage III 541 (19%) 106 (22%) 128 (26%)
Grading
G1 89 (3%) 13 (3%) 7 (1%)
G2 1294 (44%) 222 (44%) 231 (46%)
G3 1501 (51%) 268 (53%) 261 (52%)
GX 31 (1%) – 5 (1%)
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treatment period of 12 months. Thereafter, key long-term data
on surviving patients were regularly retrieved via fax forms.
Adverse drug reactions (ADRs), as defined in the CRF, were
recorded according to the regulations of German drug laws.
Database closure for the present analysis was October 2013.
Long-term follow-up is still ongoing.
2.2. Endpoint Evaluation and Statistical Aspects
Rates of baseline and treatment characteristics as well as toxicity
were comparedusing Fisher's exact test or theCochran–Armitage
trend test, respectively. The post-therapeutic disease course,
including disease recurrence, was assessed, based on standard
clinical procedures at the discretion and routine of the investiga-
tors/participating institutions, without formal requirements on
re-staging procedures. Relapse-free survival (RFS) and overall
survival (OS) were calculated as the time between the baseline
assessment before the first trastuzumab administration and the
respective event. Surviving patients without relapse were
censored at the last valid observation point. Safety data were
collected during the 12-month period of detailed documentation,
but events reported afterwards were also included in the analysis.
Event-related endpoints were analyzed using the Kaplan–
Meier method, providing 95% confidence intervals (CIs) for
event-free proportions at specific time points. Univariate
analyses comparing subgroups were performed using the log
rank test 24; hazard ratios (HR) with 95% CIs were derived
from Cox proportional hazards models.25 All prognostic
factors with an associated p value < 0.1 in univariate analysis
were included in a multivariate Cox proportional hazards
model of RFS. By backward selection, all "unnecessary" variables
were removed step-by-step, so that the final model only
contained covariates with a p value ≤ 0.05. All statistical analyses
were of an exploratory nature, with no adjustment of p values for
multiplicity made. The term "significant” was used for p ≤ 0.05.
All reported p values are two-sided.Hormone receptor status
Estrogen receptor–positive 1789 (61%) 300 (59%) 275 (54%)
Progesterone
receptor–positive
1539 (53%) 228 (45%) 224 (44%)
At least one positive 1890 (65%) 312 (62%) 288 (57%)
IHC staining for HER2




144 (5%) 49 (10%) 67 (13%)
LVEF, median (range) [%] ⁎ 65 (25–98) 65 (37 -87) 65 (40–87)
LVEF ≤ 50% 51 (2.7%) 13 (4.1%) 12 (3.8%)
Total patient numbers may deviate from n = 3940 in case of
missing values in individual parameters.
ECOG: Eastern Cooperative Oncology Group; ECG: electrocardiogram;
LVEF: left ventricular ejection fraction.
* Quantitative data available in 2508 patients only.3. Results
Overall, 4027 case documentation forms were prospectively
obtained from 339 clinics and practices across Germany for
patients starting adjuvant trastuzumab treatment between
2006 and 2011. After exclusion of clearly ineligible cases (26
patients with M1 disease; 64 patients subsequently assessed
as HER2-negative; 3 patients meeting both of these criteria),
3940 patients with HER2-positive breast cancer remained for
this analysis. Among these, 2926 (74%) were below 65 years of
age, and the remaining 1014 patients were categorized as
"elderly", equally distributed to the two subgroups, i.e. 65–
69 years (n = 507; "elderly I") and ≥ 70 years (n = 507; "elderly
II"). Twenty-nine (1%) patients were ≥80 years old.
3.1. Baseline Characteristics
Table 1 shows the patient and tumor characteristics by age
subgroup.Asexpected, performancestatuswasmore impaired in
patients aged ≥65 years than in younger patients (ECOG0: 53%vs.
65%, p < 0.0001). In this group, there were more advanced caseswith respect to the primary tumor (pT ≥ 2: 56% vs. 48%,
p < 0.0001), while lymph node involvement exhibited no clear
trend. Histopathologic characteristics did not indicate amore
favorable profile in elderly patients. Hormone receptor positivity
(both estrogen and progesterone) tended to be even lower in
Table 2 – Frequency of cardiac adverse reactions (highest
NCI CTC grade per category and patient) by age group.
Adverse reaction/age group Patients with NCI CTC grade
[n (%)]
1 2 3 4
Arrhythmia ⁎
<65 years 6 (0%) 3 (0%) – –
65–69 years 1 (0%) – – 1 (0%)
≥70 years 3 (1%) – 2 (0%) 1 (0%)
Heart function ⁎⁎
<65 years 50 (2%) 41 (1%) 18 (1%) 1 (0%)
65–69 years 4 (1%) 10 (2%) 5 (1%) 1 (0%)
≥70 years 8 (2%) 11 (2%) 10 (2%) –
Heart, other ⁎
<65 years 12 (0%) 4 (0%) – –
65–69 years 1 (0%) – – –
≥70 years 3 (1%) 1 (0%) – –
NCI CTC: National Cancer Institute Common Toxicity Criteria.
⁎ Grade 1: mild, 2: moderate; 3: severe; 4: life-threatening; disabling.
⁎⁎ Grade 1: Asymptomatic, resting ejection fraction (EF), <60–50%;
shortening fraction (SF), <30–24%. Grade 2: Asymptomatic, resting
EF <50–40%; SF <24–15%. Grade 3: Symptomatic CHF responsive to
intervention; EF <40–20%; SF <15%. Grade 4: Refractory CHF or
poorly controlled; EF <20%; intervention such as ventricular assist
device, ventricular reduction surgery, or heart transplant indicated.
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echocardiography was performed in 83% of patients. However,
while quantitative data on cardiac function (documented in
64% of patients only) did not reveal anymajor differences, the
overall rate of pathologic findings in cardiac diagnosis was
clearly increasing with age.
3.2. Adjuvant Therapy
The vast majority of patients (94%) received trastuzumab
concomitantly with (neo)adjuvant chemotherapy or afterwards.
The rate of patients receiving HER2 antibody treatment only
(with or without hormone therapy) increased with age from 5%
in younger patients to 7% in elderly I, and to 9% in elderly II
patients (p = 0.0003).Most patients (80%) received chemotherapy
after surgery, including only 74 patients (2%) who had likewise
received neoadjuvant treatment before. Overall, 14% of patients
had received chemotherapy in a neoadjuvant setting only. The
rate of pre-surgical cytotoxic treatment decreased from 19% in
younger patients to 10% and 7% in the elderly I and II groups,
respectively (p < 0.0001). The proportion of patients receiving
anthracycline-containing chemotherapy was only slightly small-
er in the elderly I group (86%) than in younger patients (90%), but
wasmarkedly lower in the elderly II group (70%). The fractions of
patients receiving taxanes as part of the adjuvant treatmentwere
69%, 57%, and 61% in the three age groups, respectively. Themost
pronounced differences between age cohorts were seen for the
combination of anthracyclines and taxanes, amounting to 59%,
44%, and 36%, respectively (p < 0.0001). In contrast, only minor
differences in the number of (neo)adjuvant chemotherapy cycles
administered were seen, with amedian of 6 cycles calculated
for the total population and mean values of 6.9, 6.6, and 6.3
for younger, elderly I, and elderly II groups, respectively. Use
of platinum derivatives steadily increased during the period of
recruitment andwasmore prevalent in older patients (8%, 10%,
and 17%, respectively; p < 0.0001).
In line with the hormone receptor expression, adjuvant
endocrine treatment was no more frequent in elderly I (53%)
and elderly II (50%) patients than in the younger group (58%).
However, the class of agents differed distinctly, with tamoxifen
(58% of patients with endocrine therapy) usedmost frequently in
younger patients, followed by aromatase inhibitors (45%) and
LHRH (luteinizing hormone-releasing hormone) analogues (13%).
The respective rates in patients aged ≥65 years were 25%, 79%,
and 1%. In total, 79% of younger patients received adjuvant
irradiation, compared to 73% of patients in the group of older
patients.
Trastuzumab was given simultaneously with chemotherapy
in 16% of patients with no major difference according to age.
Likewise, no relevant differences were detected with respect to
antibody dosage and duration. Mean treatment period was 50.9,
49.7, and 49.0 weeks in the three age cohorts. Overall, 95% of
patients received the planned dose throughout the treatment
course in all groups, while dose delays (20%, 21%, and 24%) were
only slightly more common in the oldest patients.
3.3. Toxicity
Within the framework of this observational study, trastuzumab
was generally well tolerated with predictable and manageableADRs when given as monotherapy or in combination with or
subsequent to other treatments. Table 2 presents the incidence of
cardiac toxicity of all National Cancer Institute Common Toxicity
Criteria (NCI CTC) grades, with the maximum grade experienced
by each patient stated. The rates of all-grade cardiac function
toxicity ranged from 3.7% in younger patients to 3.9% in elderly I
and 5.7% in elderly II patients (p = 0.057). The trend was more
pronounced if only grade 3 to 4 events were taken into account
(0.6%, 1.2%, and 2.0%, respectively; p = 0.0040). In the subgroup of
patients receiving adjuvant anthracyclines, the overall cardiac
dysfunction rates were not much different, with 3.5%, 3.6%, and
4.6%, in the respective three age cohorts, a finding probably
influenced by the almost unselective usage of anthracyclines in
younger patients. Quantitative data on left ventricular ejection
fraction (LVEF) at the time of antibody treatment stop were
reported in only about half of the patients across all age groups.
Mean and median values of 63.5%/64% in younger patients and
62.3%/62% in elderly I and 61.6%/61% in elderly II patients
indicated thatmost patients did not experience any deterioration
of cardiac function. When all qualitative reports on echocardiog-
raphy and electrocardiography (ECG) were taken into account,
abnormal findings were recorded at the end of trastuzumab
therapy in 6%, 12%, and 13% of patients in the three age groups.
The corresponding rates for at least one pathological finding
during the entire antibody-treatment period were 16%, 26%, and
28%. No additional signal of specific toxic effects other than
cardiac was detected in the elderly cohorts.
Trastuzumab was stopped prematurely in 8% of the younger
patients, compared to 10% and 13% in elderly I and II patients,
respectively (p = 0.0008). However, adverse events, mostly of
a cardiac type, as the reason to terminate trastuzumab therapy
were no more frequent in elderly patients, but the absolute
numbers were too small for any definitive conclusions.
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After a median follow-up period of 38.7 months overall, with
no relevant differences between the age groups (39.1, 37.8, and
38.7 months), 453 RFS events (11.5%) were observed in the
total study population, resulting in estimated relapse-free
survival of 90.0% after three years (95% confidence interval
[CI], 88.9%–91.1%) and 82.8% after five years (81.2%–84.4%).
Fig. 1 shows Kaplan–Meier curves for RFS for patients aged
<65 years and ≥65 years. In patients aged <65 years, the RFS
rate at three years amounted to 90.3% (95% CI, 89.0%–91.5%),
which was rather similar to the rate calculated for the elderly
population (89.3%, 95% CI, 87.1%–91.5%). However, due to
some separation of the curves after longer follow-up periods,
the logrank test detected an overall difference of borderline
significance (p = 0.049). HR for relapse amounted to 1.23 (95%
CI, 1.00–1.50) for patients aged ≥65 years. If the elderly group
was split, the group aged ≥70 years appeared to have a higher
frequency of events during the first 36 months, but this finding is
preliminary because of limited event counts at this stage (hazard
ratio for elderly I vs. elderly II: 1.16, 95% CI, 0.81–1.67). If age was
examined as a continuous variable in a univariate Coxmodel, HR
was 1.01 per year (95% CI, 1.00–1.02; p = 0.036). However, when
age was included in a multivariate regression model for RFS
including other established, univariately significant prognostic
factors (data not shown), age lost its independent impact on RFS
(Table 3).
Based on the actual documentation of 249 deaths (6.3%), OS
for the whole study population amounted to 96.2% after three
years (95% CI, 95.4%–96.9%) and 90.0% after five years (95% CI,
88.6%–91.4%). As shown in Fig. 2, OS at three years was higher
in patients aged <65 years (96.8% [95% CI, 96.1%–97.6%]) than
in those aged ≥ 65 years (94.2% [95% CI, 92.5%–95.9%]). This
difference was statistically significant (p = 0.0011). A similar
trend by age is also detected when comparing the elderly I and
II groups (hazard ratio: 1.51; 95% CI, 0.95–2.4), without hitherto
reaching statistical significance.< 65 y: n = 2927, 322 events
>= 65 y: n = 1013, 131 events

















n   =
n   =
2927 2891 2255 1820 1316 955 693 43
1013 979 759 596 436 323 224 12
Fig. 1 – Relapse-free survival in patien4. Discussion
Despite the high prevalence of geriatric patients in the breast
cancer population, decisions on their appropriate treatment
suffer from the lack of prospective trials specifically designed
for this subgroup, and therefore, from the lack of generally
accepted, evidence-based therapy recommendations. As a
result, the physician's, patient's, or family members' fears often
lead to suboptimal treatment strategies based on the numerical
age alone, rather than considering life expectancy, comorbidity,
and functional status.8 Although many thousands of patients
have been recruited in adjuvant breast cancer trials during the
last two decades, data on elderly patients remain sparse because
most clinical trials tend to exclude the elderly population, or
specific analyses are not publicly available. For example, six
large randomized trials including about 10,000 patients receiving
adjuvant antibody treatment inHER2-positive breast cancerwere
performed. Although the cutoff for "elderly" was defined as
60 years, only about 1000 of these patients could be included in
recent systematic reviews on this important subpopulation.7,20,21
In the HERA study, only 16% of patients were aged ≥60 years.12
Thus, prospective patient series as described in our non-
interventional observation study still seem to provide the
most reliable information on patient groups older than 65 years
or even 70 years.With a proportion ofmore than one out of four
patients being over 65 years of age, we provide data on this, to
our knowledge, largest hitherto published group of elderly
patients treated with adjuvant trastuzumab.
Albeit this still remains a controversial topic, most of the
reviews on breast cancer in elderly patients conclude that this
age group typically suffers from biologically less aggressive,
predominantly hormone receptor–positive disease.2,5,21,26 For
example,Montroni et al.27 reported that in a retrospective series
of 422 patients aged ≥70 years, only 23% had G3 grading, and
only 11% were hormone receptor–negative. Large US datasets,
derived from US registries starting in the 1970s, show a steadylogrank test: p = 0.049, two-sided
80 90 100 110 120 130
( < 65 years )
( >= 65 years )
8 248 89 18 5 2
7 48 15 4 0 0
ts aged <65 years and ≥65 years.
Table 3 –Multivariate regression analysis of prognostic
factors for relapse-free survival.
Prognostic factor
(first group mentioned is




Age: per year, continuous 1.01 (0.997–1.01)
p = 0.24
Primary tumor: pT1/cis vs. pT2–4 1.93 (1.55–2.40)
p < 0.0001
Lymph nodes: pN0 vs. pN+ 2.11 (1.71–2.61)
p < 0.0001
Grading: G1/2 vs. G3 1.19 (0.97–1.47)
p = 0.092
Hormone receptor status: neg. vs. pos. 0.58 (0.47–0.71)
p < 0.0001
ECOG performance: 0 vs. 1–4 1.11 (0.91–1.36)
p = 0.29
HR: hazard ratio; CI: confidence interval.
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S-phase fraction with rising age.28 However, our data (Table 1)
suggest that this does not hold true in the sub-subpopulation of
elderly patients with HER2-positive disease, as the respective
proportions with G3 and hormone receptor–negative tumors
were similar to or even slightly higher than those in the younger
cohort. This discrepancymay be explained by the fact that only
6%of patients participating in the study reported byMontroni et
al. were HER2-positive according to the usual standards. It is
also in line with SEER-Medicare data on patients ≥66 years who
had received adjuvant trastuzumab treatment, documenting a
high prevalence (42%) of hormone receptor negativity (although
the respective findings on the corresponding younger population
are not provided).29 Obviously, the fact is that HER2 overexpres-
sion levels off differences in tumor biology otherwise detected
between older and younger patients. On the other hand, our
findingofmore advancedTandNstages in theelderly subgroups
is in line with other patient series that disregarded HER2 status.5< 65 years: n = 2927, 167 events
>= 65 years: n = 1013, 82 events














n   =
n   =
2927 2902 2311 1921 1426 1051 764 48
1013 988 776 628 464 347 237 13
Fig. 2 – Overall survival in patientsThere is no major prospective study on the comparison of
trastuzumab-related cardiotoxicity betweenyounger andelderly
patients with early breast cancer. Again, the large pivotal,
randomized studies produced no relevant data on this issue
due to the age limit at selection, and, more importantly, due to
the strict exclusion of patients with cardiac risk factors. An age
trend for cardiotoxicity among the younger patients was not
consistently shown in these trials.While theUS studies revealed
an increasing risk of cardiotoxicity with age, this trend was not
evident in HERA,5,30 possibly due to the investigators’ option to
individually tailor the chemotherapy according to age and/or
comorbidity. A recent SEER database study in women aged 67 to
94 years (constituting only 1.9% of the study cohort) revealed a
rather high rate (>15%) of administrative code claims of "heart
failure" or "cardiomyopathy" after one year of treatment with
adjuvant trastuzumab.31 This contrasts with the low incidence
of cardiac function toxicity (approx. 5%, all grades) in the elderly
patients of our prospective observation. On the other hand, our
data significantly show a comparatively higher, and increasing
risk in patients beyond 65 years, remaining, however, within
acceptable limits. Thus, our data confirm the general recom-
mendations hitherto based on small patient series from
individual institutions only, that adjuvant trastuzumab is
feasible also in elderly/comorbid patients, if carefully managed
and monitored.6,21
Twometa-analyses of the randomized studies of trastuzumab
vs. control addressed the age-dependent efficacy of trastuzumab
with respect to RFS.7,20 The Cochrane review included meta-
regression analyses of some prognostic factors. When both the
HERA and the joint analysis of NCCTG N9831 and NSABP B-31
were combined, age above 60 years was associated with an only
weak trend towards decreased treatment benefit (relative HR =
1.14; 95% CI, 0.63–2.09). However, the individual results from the
two trial analyseswereextremelyheterogeneous; relativeHRwas
0.82 in favor of elderly patients in theUS studies compared to 1.52
inHERA (i.e. no significant treatment effect detected in theelderly
group). This discrepancy was not further discussed by thelogrank test: p = 0.0011, two-sided
0 80 90 100 110 120 130
( < 65 years )
( >= 65 years )
9 284 98 19 5 2
4 53 17 5 1 0
aged <65 years and ≥65 years.
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numbers and the wide CIs. The second meta-analysis7 of the
same trials confirmed this discrepancy, albeit to a lower extent.
The latter is due to the fact that the second overview, although
published more recently, used the earliest data from HERA
published12 instead of the updated ones.13 Thus, the randomized
trials remain rather inconclusive with respect to age effects.
However, our data clearly suggest a comparable benefit of
adjuvant trastuzumab treatment in elderly and younger
patients. The slight difference detected in the univariate RFS
analysis (Fig. 1) might be attributable to confounding factors,
and consequently vanished in the multivariate model. The
significant disadvantage exhibited in the overall survival curves
can be easily explained by the expected different background
mortality in older patients, regardless of the tumor disease,
especially since our oldest patient was 100 years of age.
There are several limitations in our study. Most importantly,
we neither have data on a comparable patient cohort without
trastuzumab treatment nor information on an imaginable
process of excluding specific patients from the targeted
antibody treatment despite of HER2 positivity. With respect
to toxicity, our records show the frequency of cardiac assess-
ments in routinepractice to be clearly lower than recommended,
possibly leading to an underestimation of risks. Moreover, the
scope of our recorded data did not allow any quantified geriatric
assessment, which would probably be more appropriate for
treatment decisions than chronological age.
In summary, our study comprises a representative data
set, reflecting the routine treatment decisions and outcome
assessments in patients receiving trastuzumab in Germany,
without any restriction by protocol requirements and proce-
dures. It shows the underlying biological aggressiveness of
HER2-overexpressing tumors, even when diagnosed in old
age. Although cardiotoxicity increased significantly with age,
we consider antibody treatment feasible in the vast majority
of elderly patients. Our long-term outcome data seem to
confirm the beneficial findings from the pivotal studies also in a
large group of elderly patients who are not, or only marginally,
represented in the randomized trials. Nevertheless, results
from ongoing randomized studies of HER2-targeted therapies,
specifically focusing on elderly patients, e.g. the RESPECT trial,32
are eagerly awaited.Funding
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